Tottori

Researchers are evaluating the effectiveness and safety of two medications, ozanimod and azathioprine, for treating steroid-dependent ulcerative colitis (UC) in everyday clinical settings in Japan. This study focuses on adults with UC who require steroids and aims to compare these treatments based on real-world medical practice. It seeks to understand how well these drugs help patients avoid steroid use while managing their symptoms. Participants will receive either ozanimod or azathioprine according to product labeling and medical guidelines. The study includes patients who have been on oral steroids at doses of 30 mg/day or higher and have started the study drug after beginning steroid treatment, with the two medications given alongside steroids but not started on the same day. The ozanimod group includes patients who still have active symptoms at treatment start, while the azathioprine group includes those who began treatment after February 2019. During the study, researchers will track the proportion of participants who achieve steroid-free symptomatic remission at 12, 24, and 52 weeks. Participants will be monitored through medical chart reviews to assess symptom changes and treatment safety. The study involves careful observation of medication use, symptom scores, and the need for ongoing steroid therapy to evaluate long-term treatment outcomes.

Researchers are evaluating the effects of hypothermia versus normothermia on patients who have experienced out-of-hospital cardiac arrest and received extracorporeal cardiopulmonary resuscitation (ECPR). This cluster randomized trial, called the SAVE-J NEUROTHERM trial, aims to compare mortality risk, neurological outcomes, and adverse events between these temperature control strategies. The study addresses the ongoing debate about optimal temperature management after cardiac arrest, especially in patients treated with ECPR using extracorporeal membrane oxygenation (ECMO).

Researchers are evaluating the overall survival of women with stage I epithelial ovarian cancer following comprehensive staging surgery. This phase III trial compares the effects of adjuvant chemotherapy versus observation without chemotherapy in this patient group. Patients are randomly assigned based on histologic type, enrollment facility, and clinical staging according to the FIGO system. Participants are divided into two groups. Group A receives adjuvant chemotherapy, which includes either Paclitaxel plus Carboplatin or Docetaxel plus Carboplatin, administered every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. Group B undergoes observation only, with no chemotherapy given. The study treatment starts within eight weeks after comprehensive staging surgery. During the study, participants undergo regular assessments to monitor survival status up to 60 months from randomization. Researchers collect data including clinical evaluations, imaging, and laboratory tests as needed. Safety is closely monitored, and participants provide informed consent before enrollment. The trial aims to determine whether adjuvant chemotherapy improves survival compared to observation alone in this patient population.